阿森迪斯制药
ASND
225.25
-1.37
-0.60%
阿森迪斯制药
US · ASND
#1127 按市值排名
上市于 2015
225.25
-1.37
-0.60%
实时 - 追踪5344个代码 - 心跳于454秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量增加了7家。
- 机构持股总比例上升了0.2个百分点。
机构持股
- 机构持股比例
- 103.62% +0.16pp
- 机构数量
- 373 +7
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund68.00%
VC/PE Fund18.25%
Hedge Fund13.02%
Public Company2.22%
Private Company0.94%
Government Pension Fund0.58%
Sovereign Wealth Fund0.33%
Insurance Company0.16%
主要股东 截至 2026-06-30
RA Capital Management, L.P.
15.66% · 10.28M 股
T. Rowe Price Group, Inc.
11.99% · 7.88M 股
Avoro Capital Advisors LLC
7.78% · 5.11M 股
Westfield Capital Management Company, L.P.
7.31% · 4.80M 股
Janus Henderson Group plc
5.56% · 3.65M 股
FMR
5.40% · 3.55M 股
Capital Research
4.49% · 2.95M 股
Artisan Partners Limited Partnership
4.01% · 2.63M 股
BlackRock
3.37% · 2.21M 股
MFS Investment Management
2.86% · 1.88M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 6次买入 · 4次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Scott Smith | CFO, Executive VP & Member of Executive Board | 0.01% |
| Lars Holtug | Independent Director | 0.01% |
| Jean-Jacques Bienaime | Non-Executive Director | 0.00% |
| Albert Cha | Independent Chairperson | -- |
| Jan Mikkelsen | President, CEO, Member of Executive Board & Executive Director | -- |
| Michael Jensen | Executive VP, Chief Legal Officer & Member of the Executive Board | -- |
| Flemming Jensen | Executive Vice President of Product Supply & Quality - Endocrinology Rare Diseases | -- |
| Pedersen Anni Lotte Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board | -- |
| Mads Bodenhoff | Senior VP of Finance & Principal Accounting Officer | -- |
| William Fairey | Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-07 | Mads Bodenhoff | Senior VP of Finance & Principal Accounting Officer | Derivative Exercise and Sale | -3,000 | $110.00–270.19 |
| 2026-09-01 | Lars Holtug | Independent Director | Open Market Disposition | -236 | $264.13 |
| 2026-08-13 | Jean-Jacques Bienaime | Non-Executive Director | Open Market Acquisition | +2,000 | $245.85–246.91 |
| 2026-06-01 | Scott Smith | CFO, Executive VP & Member of Executive Board | Open Market Acquisition | +100 | $219.00 |
| 2026-05-28 | Jean-Jacques Bienaime | Non-Executive Director | Open Market Acquisition | +500 | $222.30–223.76 |
| 2026-05-28 | Scott Smith | CFO, Executive VP & Member of Executive Board | Open Market Acquisition | +250 | $223.32 |
| 2026-05-25 | Jean-Jacques Bienaime | Non-Executive Director | Open Market Acquisition | +400 | $236.24–239.37 |
| 2026-05-10 | Flemming Jensen | Executive Vice President of Product Supply & Quality - Endocrinology Rare Diseases | Open Market Disposition | -19,460 | $238.49 |
| 2026-04-13 | Jean-Jacques Bienaime | Non-Executive Director | Derivative Sale to Issuer | -9,160 | -- |
| 2026-04-13 | Jean-Jacques Bienaime | Non-Executive Director | Other Derivative Acquisition | +9,160 | $249.84 |
| 2026-03-22 | Jean-Jacques Bienaime | Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Albert Cha | Independent Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Jan Mikkelsen | President, CEO, Member of Executive Board & Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Michael Jensen | Executive VP, Chief Legal Officer & Member of the Executive Board | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Flemming Jensen | Executive Vice President of Product Supply & Quality - Endocrinology Rare Diseases | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Pedersen Anni Lotte Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Mads Bodenhoff | Senior VP of Finance & Principal Accounting Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | William Fairey | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Lisa Morrison | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Scott Smith | CFO, Executive VP & Member of Executive Board | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
阿森迪斯制药 讨论区 0 条评论